CN113993852B - 用于制备ClC-1氯离子通道抑制剂的方法 - Google Patents
用于制备ClC-1氯离子通道抑制剂的方法 Download PDFInfo
- Publication number
- CN113993852B CN113993852B CN202080043796.2A CN202080043796A CN113993852B CN 113993852 B CN113993852 B CN 113993852B CN 202080043796 A CN202080043796 A CN 202080043796A CN 113993852 B CN113993852 B CN 113993852B
- Authority
- CN
- China
- Prior art keywords
- phenoxy
- dihydroisoxazol
- bromo
- butoxy
- propionic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19181262 | 2019-06-19 | ||
| EP19181262.7 | 2019-06-19 | ||
| PCT/EP2020/067065 WO2020254554A1 (en) | 2019-06-19 | 2020-06-19 | Process for the preparation of clc-1 chloride channel inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113993852A CN113993852A (zh) | 2022-01-28 |
| CN113993852B true CN113993852B (zh) | 2024-12-17 |
Family
ID=66999603
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080043796.2A Active CN113993852B (zh) | 2019-06-19 | 2020-06-19 | 用于制备ClC-1氯离子通道抑制剂的方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12221425B2 (https=) |
| EP (1) | EP3986878B1 (https=) |
| JP (1) | JP7595945B2 (https=) |
| KR (1) | KR102900834B1 (https=) |
| CN (1) | CN113993852B (https=) |
| AR (1) | AR119198A1 (https=) |
| AU (1) | AU2020298092B2 (https=) |
| BR (1) | BR112021025588A2 (https=) |
| CA (1) | CA3137672A1 (https=) |
| ES (1) | ES3000437T3 (https=) |
| HU (1) | HUE069104T2 (https=) |
| IL (1) | IL287901B2 (https=) |
| MX (1) | MX2021013507A (https=) |
| PL (1) | PL3986878T3 (https=) |
| SG (1) | SG11202111122RA (https=) |
| TW (1) | TWI849152B (https=) |
| WO (1) | WO2020254554A1 (https=) |
| ZA (1) | ZA202107653B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4593829A1 (en) | 2022-09-30 | 2025-08-06 | NMD Pharma A/S | Compositions and methods for treating myasthenia gravis |
| WO2024180199A1 (en) | 2023-03-02 | 2024-09-06 | Nmd Pharma A/S | Compositions and methods for treating charcot–marie–tooth disease |
| JP2026508357A (ja) | 2023-03-02 | 2026-03-10 | エヌエムディー ファーマ エー／エス | 脊髄性筋萎縮症を処置するための組成物及び方法 |
| EP4731200A1 (en) | 2023-06-20 | 2026-04-29 | NMD Pharma A/S | Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301010D0 (sv) * | 2003-04-07 | 2003-04-07 | Astrazeneca Ab | Novel compounds |
| GB0422057D0 (en) * | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| GB0524428D0 (en) * | 2005-11-30 | 2006-01-11 | 7Tm Pharma As | Medicinal use of receptor ligands |
| WO2009097970A1 (de) * | 2008-02-05 | 2009-08-13 | Sanofi-Aventis | Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel |
| JP2015505560A (ja) * | 2012-02-03 | 2015-02-23 | ゾエティス・エルエルシー | 抗寄生虫薬としてのキラルイソオキサゾリンアゼチジン誘導体の製造法 |
| MX389242B (es) | 2015-06-15 | 2025-03-20 | Nmd Pharma As | Compuestos para su uso en el tratamiento de trastornos neuromusculares |
| US10385028B2 (en) * | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| TWI780281B (zh) | 2017-12-14 | 2022-10-11 | 丹麥商Ｎｍｄ藥品公司 | 用於治療神經肌肉病症的化合物 |
-
2020
- 2020-06-19 BR BR112021025588A patent/BR112021025588A2/pt unknown
- 2020-06-19 IL IL287901A patent/IL287901B2/en unknown
- 2020-06-19 ES ES20734157T patent/ES3000437T3/es active Active
- 2020-06-19 SG SG11202111122RA patent/SG11202111122RA/en unknown
- 2020-06-19 EP EP20734157.9A patent/EP3986878B1/en active Active
- 2020-06-19 CN CN202080043796.2A patent/CN113993852B/zh active Active
- 2020-06-19 HU HUE20734157A patent/HUE069104T2/hu unknown
- 2020-06-19 TW TW109120910A patent/TWI849152B/zh active
- 2020-06-19 US US17/619,312 patent/US12221425B2/en active Active
- 2020-06-19 JP JP2021569300A patent/JP7595945B2/ja active Active
- 2020-06-19 MX MX2021013507A patent/MX2021013507A/es unknown
- 2020-06-19 CA CA3137672A patent/CA3137672A1/en active Pending
- 2020-06-19 AR ARP200101735A patent/AR119198A1/es unknown
- 2020-06-19 AU AU2020298092A patent/AU2020298092B2/en active Active
- 2020-06-19 KR KR1020217037880A patent/KR102900834B1/ko active Active
- 2020-06-19 WO PCT/EP2020/067065 patent/WO2020254554A1/en not_active Ceased
- 2020-06-19 PL PL20734157.9T patent/PL3986878T3/pl unknown
-
2021
- 2021-10-11 ZA ZA2021/07653A patent/ZA202107653B/en unknown
Non-Patent Citations (1)
| Title |
|---|
| 趋化因子受体2抑制剂PF-04136309的合成研究;颜延宁;周鑫鑫;;化学试剂;20201231(第09期);1125-1129 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3986878A1 (en) | 2022-04-27 |
| HUE069104T2 (hu) | 2025-02-28 |
| BR112021025588A2 (pt) | 2022-02-01 |
| IL287901A (en) | 2022-01-01 |
| PL3986878T3 (pl) | 2025-01-20 |
| EP3986878C0 (en) | 2024-09-25 |
| CN113993852A (zh) | 2022-01-28 |
| TWI849152B (zh) | 2024-07-21 |
| US12221425B2 (en) | 2025-02-11 |
| KR102900834B1 (ko) | 2025-12-16 |
| AU2020298092A1 (en) | 2021-11-18 |
| SG11202111122RA (en) | 2021-11-29 |
| MX2021013507A (es) | 2021-12-10 |
| TW202115003A (zh) | 2021-04-16 |
| AU2020298092A8 (en) | 2025-04-24 |
| IL287901B2 (en) | 2025-02-01 |
| CA3137672A1 (en) | 2020-12-24 |
| WO2020254554A1 (en) | 2020-12-24 |
| ES3000437T3 (en) | 2025-02-28 |
| JP2022537493A (ja) | 2022-08-26 |
| JP7595945B2 (ja) | 2024-12-09 |
| IL287901B1 (en) | 2024-10-01 |
| AU2020298092B2 (en) | 2025-09-25 |
| ZA202107653B (en) | 2023-05-31 |
| EP3986878B1 (en) | 2024-09-25 |
| KR20220022895A (ko) | 2022-02-28 |
| AR119198A1 (es) | 2021-12-01 |
| US20220298124A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113993852B (zh) | 用于制备ClC-1氯离子通道抑制剂的方法 | |
| TWI345562B (en) | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof | |
| EP2927217B1 (en) | Amide compound and pharmaceutical application therefor | |
| EP1024137B1 (en) | Resolution of amines | |
| UA118369C2 (uk) | Сполуки, що інгібують активність lrrk2 кінази | |
| CA2977614A1 (en) | Cyclic amine derivative and pharmaceutical use thereof | |
| AU2015362394B2 (en) | Dihydropyrimidine-2-one compounds and medicinal uses thereof | |
| CN118525016A (zh) | 蛋白酪氨酸磷酸酶抑制剂及其使用方法 | |
| EP3237379B1 (en) | Process for preparing alpha-carboxamide pyrrolidine derivatives | |
| Erhardt et al. | Conformational analogs of dopamine. Synthesis and pharmacological activity of (E)-and (Z)-2-(3, 4-dihydroxyphenyl) cyclopropylamine hydrochlorides | |
| KR20180032585A (ko) | 피페라진 유도체 | |
| JP7662196B2 (ja) | 神経筋障害の治療のための化合物 | |
| HK40068865B (en) | Process for the preparation of clc-1 chloride channel inhibitors | |
| HK40068865A (en) | Process for the preparation of clc-1 chloride channel inhibitors | |
| EP1937248B1 (en) | Alcanoic acid amides substituted by saturated o-heterocycles | |
| US20100048549A1 (en) | Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4 | |
| WO2017046096A1 (en) | Non-steroidal glucocorticoid receptor modulators for local drug delivery | |
| Schow et al. | Diastereoselective synthesis of the antibiotic L-azatyrosine | |
| EP3939976B1 (en) | Prodrug of caspase inhibitor | |
| KR100758317B1 (ko) | 몰폴린-2-온 유도체를 포함하는 ｔ-형 칼슘 채널 차단용조성물 | |
| CA2353972A1 (en) | Processes for the preparation of novel naphthyridine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |